These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32247610)

  • 1. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
    Inoue-Yamauchi A; Oda H
    Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
    Song KA; Niederst MJ; Lochmann TL; Hata AN; Kitai H; Ham J; Floros KV; Hicks MA; Hu H; Mulvey HE; Drier Y; Heisey DAR; Hughes MT; Patel NU; Lockerman EL; Garcia A; Gillepsie S; Archibald HL; Gomez-Caraballo M; Nulton TJ; Windle BE; Piotrowska Z; Sahingur SE; Taylor SM; Dozmorov M; Sequist LV; Bernstein B; Ebi H; Engelman JA; Faber AC
    Clin Cancer Res; 2018 Jan; 24(1):197-208. PubMed ID: 29051323
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
    Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
    Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.
    Yoon H; Choi YL; Song JY; Do I; Kang SY; Ko YH; Song S; Kim BG
    PLoS One; 2014; 9(2):e88587. PubMed ID: 24523919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
    Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
    Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
    Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
    Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.